Eribulin-based antibody-drug conjugates and methods of use
US10322192B2 · kind B2 · utility
10Cited by
66References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2018 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | Mar 4, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.